Skip to main content
Log in

RA decisions in Europe based on efficacy and costs, not ICERs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. cost effectiveness

Reference

  • Hifinger M, et al. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. Annals of the Rheumatic Diseases : 17 May 2016. Available from: URL: http://doi.org/10.1136/annrheumdis-2016-209202

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

RA decisions in Europe based on efficacy and costs, not ICERs. PharmacoEcon Outcomes News 754, 28 (2016). https://doi.org/10.1007/s40274-016-3098-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3098-x

Navigation